Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: BostonView who wrote (994)	8/29/2000 5:52:19 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

August 29, 2000 CIBA, QLT Get US FDA Priority Review Status For Visudyne VANCOUVER -- CIBA Vision Corp. and QLT Inc.'s (QLTI) have received U.S. Food and Drug Administration priority-review status for their supplemental new drug application for Visudyne therapy. As reported, the application is to expand Visudyne therapy for the treatment of eye diseases beyond age-related macular degeneration. In a press release, the companies said the status means that the FDA intends to act on the application within six months. CIBA Vision researches, develops and makes optical and ophthalmic products and services. CIBA Vision is the eye care unit of Novartis AG (NVS), a healthcare company. QLT Inc. develops and commercializes proprietary pharmaceutical products for use in photodynamic therapy. Company Web Sites: cibavision.com and qltinc.com